Results 221 to 230 of about 10,420,359 (296)

Urinary dysfunction in myasthenia Gravis: a cross-sectional case-control study. [PDF]

Neurol Sci
Shihada K, Gorenshtein A, Wolfe GI, Shelly S.   +3 more
europepmc   +1 more source

Crucial parameters for precise copy number variation detection in formalin‐fixed paraffin‐embedded solid cancer samples

Molecular Oncology, EarlyView.
This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.
Hanne Goris, Vasiliki Siozopoulou, Léon C van Kempen, Anne Sieben, Ella Roelant, Stig Hellemans, Elyne Backx, Laure Sorber, Koen De Winne, Senada Koljenović, Karen Zwaenepoel   +10 more
wiley   +1 more source

Enamel Defects Among Orphanage Children: A Multi-Country Case-Control Study. [PDF]

Int Dent J
Sabbagh HJ, Barry MJ, Al-Batayneh OB, Alshobaili YT, Sennain SL, Al-Khanati NM, Nagi BM, Al-Rai S, Nabil N, Yassin R, Quritum M, Aboushady NAA, Hassan M, Yousufi S, Khattab NMA, Khader YS, Abushgair S, Taha D, Arnabeh G, Elareibi I, Fakron S, Jameel ASA, Bagher SM, Elkhodary HM, Alamoudi RA.   +24 more
europepmc   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Labor Induction with Synthetic Oxytocin and Infantile Colic: A Case-Control Study. [PDF]

Medicina (Kaunas)
Suárez-Fraga C, Rodríguez-Nogueira Ó, Pinto-Carral A, Leirós-Rodríguez R, Álvarez-Álvarez MJ.   +4 more
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Platelet lipidome alterations in septic shock: a matched case-control study. [PDF]

Res Pract Thromb Haemost
de Cartier d'Yves E, Dechamps M, Ambroise J, Forest A, Daneault C, Campion A, Robaux V, De Poortere J, Octave M, Ginion A, Pirotton L, Muscia G, Tersteeg C, Gruson D, Van Dievoet MA, Douxfils J, Haguet H, Morimont L, Derive M, Montiel V, Bertrand L, Rosiers CD, Horman S, Beauloye C.   +23 more
europepmc   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Uninsured Patients Under Dialysis in Greece: A Case-Control Study. [PDF]

Cureus
Revela I, Gkika V, Gkogka E, Smirloglou D, Pallas Nikolov C, Palla S, Chelioti E, Kalaitzidis RG.   +7 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source